

Dar Aldawa Signs License and Supply Agreement with Galenicum to Expand Access to Key Therapies Across MENA



Dar Aldawa Development and Investment Co. Ltd is pleased to announce the signing of a licensing and supply agreement with Galenicum, a global pharmaceutical company, to strengthen its therapeutic portfolio across the Middle East and North Africa (MENA) region.

Under the terms of the agreement, Dar Aldawa will license and commercialize a select range of Galenicum's products in the MENA region, focusing on the diabetes and cardiovascular chronic therapeutic areas, two of the region's most pressing public health priorities. The partnership will allow Dar Aldawa to expand its treatment offering, improve patient access to high-quality medicines, and further reinforce its position as a trusted healthcare partner across the region.

About Dar Aldawa Development and Investment Co. Ltd

Headquartered in Jordan, Dar Aldawa Development and Investment Co. Ltd is a leading regional pharmaceutical company dedicated to expanding access to high-quality, affordable medicines across the MENA region. Through strategic partnerships and an extensive distribution network, Dar Aldawa has established a strong track record in licensing, commercialization, and market expansion, with a continued focus on addressing unmet medical needs and supporting the region's healthcare systems.

About Galenicum

Galenicum is a global pharmaceutical company headquartered in Esplugues de Llobregat, Barcelona, Spain, specializing in the development, manufacturing, and commercialization of generic medicines and value-added generics. Galenicum is a trusted partner for local and regional pharmaceutical companies, delivering affordable, high-quality products to more than 70 countries worldwide.

The company offers a diversified portfolio in key therapeutic areas, including cardiovascular, central nervous system, pain management, anti-infectives and GLP-1s. Galenicum operates a state-of-the-art manufacturing facility and dedicated R&D centers, supported by a committed team.

Dar Aldawa looks forward to working closely with Galenicum to bring these important therapies to patients across MENA, furthering its shared vision of improving healthcare